Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck
Phase 2
Withdrawn
- Conditions
- Head and Neck CancerCarcinoma, Squamous Cell
- Registration Number
- NCT00233636
- Lead Sponsor
- AstraZeneca
- Brief Summary
The aim of the study is to determine if Iressa added to radiotherapy is effective and safe in shrinking tumour dimensions.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
- Histologically Confirmed locally advanced Squamous Cell Carcinoma of Head and neck
- At least one measurable tumour lesion
Exclusion Criteria
- No previous treatment such as chemotherapy, radiotherapy and/or surgery for Carcinoma Head and Neck
- No other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
- Any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Tumour Response Rate, as complete response (CR) and partial response (PR) . Six months after Last Patient In.
- Secondary Outcome Measures
Name Time Method Time to progression, Overall survival, Duration of response. Six months after Last Patient In.
Trial Locations
- Locations (1)
Research Site
🇮🇹Ragusa, Italy